| Outcome Measures: |
Primary: Degree of HLA sensitization, The difference between the two treatment arms in the degree of HLA sensitization at 2-years measured as cPRA (%)., 2 years | Secondary: Mortality for any reason, The difference between the two treatment arms at 2-years on mortality for any reason, 2 years|Days of hospitalization for any reason, The difference between the two treatment arms at 2-years on days of hospitalization for any reason, 2 years|Percentage of patients effectively relisted during follow-up, The difference between the two treatment arms at 2-years on percentage of patients effectively relisted during follow-up, 2 years|Percentage of patients transplanted, The difference between the two treatment arms at 2-years on percentage of patients transplanted, 2 years|Percentage of patients delisted for any reason, The difference between the two treatment arms at 2-years on percentage of patients delisted for any reason, 2 years|Incidence of infection, The difference between the two treatment arms at 2-years on incidence of infection, 2 years|Incidence of cardiovascular events, The difference between the two treatment arms at 2-years on incidence of cardiovascular events, 2 years|Incidence of cancer, The difference between the two treatment arms at 2-years on incidence of cancer, 2 years|Incidence of graft-intolerance syndrome requiring graft nephrectomy or percutaneous embolization of the non-functioning graft, The difference between the two treatment arms at 2-years incidence of graft-intolerance syndrome requiring graft nephrectomy or percutaneous embolization of the non-functioning graft, 2 years|Erythropoietin resistance index, The difference between the two treatment arms at 2-years on erythropoietin resistance index, 2 years|Residual renal function, The difference between the two treatment arms at 2-years on residual renal function, 2 years|Number of circulating memory B-cells, The difference between the two treatment arms at 2-years on number of circulating memory B-cells, 2 years|Adverse events, The difference in the incidence of adverse events (AE) in the two treatment arms, 2 years
|
